Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001591677 | SCV001815707 | likely pathogenic | Orofaciodigital syndrome type 14 | 2020-11-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001882709 | SCV002160650 | uncertain significance | not provided | 2022-10-17 | criteria provided, single submitter | clinical testing | The C2CD3 gene has multiple clinically relevant transcripts. This variant occurs in alternate transcript NM_001286577.1, and corresponds to NM_015531.5:c.*439del in the primary transcript. This sequence change creates a premature translational stop signal (p.Cys2001Alafs*9) in the C2CD3 gene. While this is anticipated to result in nonsense mediated decay, it is not known whether truncations in this region of the protein cause disease. This variant is present in population databases (no rsID available, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with C2CD3-related conditions. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Laboratory for Molecular Medicine, |
RCV001882709 | SCV004847457 | uncertain significance | not provided | 2024-02-27 | criteria provided, single submitter | clinical testing | The p.Cys2001AlafsX9 (c.6001delT) variant in C2CD3 has not been previously reported in individuals with orofaciodigital syndrome type 14 but has been reported by other clinical laboratories in ClinVar (Variation ID 1213728). It has also been identified in 0.007% (1/15282) of Admixed American chromosomes by gnomAD (http://gnomad.broadinstitute.org, v.3.1.2). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 2001 and leads to a premature termination codon 9 amino acids downstream. This variant however is present in a transcript that is not predominantly expressed in the relevant tissues of interest and is therefore not the primary transcript for this gene. In the primary transcript (NM_015531.5), this variant occurs in the 3’UTR (c.*439). Therefore, the functional impact of this variant is unknown. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PVS1_Moderate, PM2_Supporting. |